What Is Mounjaro (Tirzepatide)?

Tirzepatide's Mechanism: Why Two Receptors Matter

Tirzepatide is the first approved drug to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor with a single molecule. GLP-1 receptor agonists like semaglutide were already well-established for blood sugar control and appetite suppression. Adding GIP receptor activity appears to amplify those effects in ways that a single-target drug cannot match.

How GLP-1 Receptor Activation Works

GLP-1 is a hormone secreted by intestinal L-cells after meals. When the GLP-1 receptor is activated pharmacologically, the result is a chain of coordinated effects: insulin secretion rises in proportion to blood glucose, glucagon release falls, gastric emptying slows, and appetite-regulating centers in the hypothalamus receive satiety signals. These combined actions lower post-meal glucose spikes and reduce caloric intake over time. A 2021 review in Pharmacological Reviews describes the full signaling cascade in detail.

How GIP Receptor Activation Adds to That

GIP is released by intestinal K-cells and has traditionally been described as an incretin hormone. Its role in energy metabolism is more complex than once thought. Animal and human data suggest GIP receptor activation enhances insulin secretion from beta cells, may improve insulin sensitivity in fat tissue, and could reduce nausea caused by GLP-1 receptor activation alone. A 2022 paper in Cell Metabolism showed tirzepatide's GIP component contributes meaningfully to fat mass reduction independent of the GLP-1 component.

The Single-Molecule Design

Eli Lilly engineered tirzepatide as a 39-amino-acid peptide with a C20 fatty diacid modification that extends its half-life to approximately five days, enabling once-weekly dosing. The original pharmacology paper published in Science Translational Medicine demonstrated balanced GIP/GLP-1 co-agonism in preclinical models with a potency ratio designed to produce additive rather than competing receptor effects.

FDA Approval History and Regulatory Status

Diabetes Approval (May 2022)

The FDA approved tirzepatide under the brand name Mounjaro on May 13, 2022, for adults with type 2 diabetes as an adjunct to diet and exercise. The FDA approval letter and prescribing information are accessible via the FDA Drugs database. The approval was based primarily on the six SURPASS phase 3 trials.

Obesity Approval (November 2023)

On November 8, 2023, the FDA approved tirzepatide 2.5 mg to 15 mg under the brand name Zepbound for chronic weight management in adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. The Zepbound approval announcement is on the FDA newsroom.

The SURPASS Trials: Tirzepatide for Type 2 Diabetes

The SURPASS program comprised six randomized controlled trials enrolling more than 10,000 patients with type 2 diabetes across different treatment backgrounds and comparators.

SURPASS-2: Head-to-Head Against Semaglutide 1 mg

SURPASS-2 (N=1,879) directly compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg (Ozempic) over 40 weeks, all added to metformin. Published in the New England Journal of Medicine in 2021, the trial showed:

• Tirzepatide 5 mg reduced A1C by 2.09 percentage points vs. 1.86 for semaglutide 1 mg.
• Tirzepatide 10 mg reduced A1C by 2.37 percentage points.
• Tirzepatide 15 mg reduced A1C by 2.58 percentage points (P<0.001 for all doses vs. Comparator).
• Weight loss was 7.8 kg, 9.3 kg, and 11.2 kg for the three tirzepatide doses vs. 5.7 kg for semaglutide 1 mg.

The SURPASS-2 authors concluded that "tirzepatide was superior to semaglutide with respect to reduction in A1C and body weight at 40 weeks." NEJM, 2021

SURPASS-CVOT: Cardiovascular Outcomes

SURPASS-CVOT is a dedicated cardiovascular outcomes trial for tirzepatide in patients with type 2 diabetes and established cardiovascular disease or high risk. Enrollment exceeded 13,000 participants. The trial registry entry is available at ClinicalTrials.gov via the NIH. Results published in 2024 confirmed tirzepatide was non-inferior to dulaglutide (Trulicity) on major adverse cardiovascular events over a median follow-up of approximately 36 months.

SURPASS-1 Through SURPASS-6

Across all six SURPASS trials, tirzepatide at 15 mg consistently produced A1C reductions between 1.87 and 2.58 percentage points, and body weight reductions between 7.0 and 12.9 kg depending on background therapy and population. A pooled analysis is summarized in Diabetes Care.

The SURMOUNT Trials: Tirzepatide for Weight Management

SURMOUNT-1: The Landmark Obesity Trial

SURMOUNT-1 (N=2,539) enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity but without diabetes. Participants received tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, once weekly for 72 weeks alongside lifestyle intervention. Published in the New England Journal of Medicine in 2022.

Key results at 72 weeks:

• Tirzepatide 5 mg: mean weight loss of 15.0% vs. 3.1% placebo.
• Tirzepatide 10 mg: mean weight loss of 19.5%.
• Tirzepatide 15 mg: mean weight loss of 20.9% (a later analysis including all completers reached 22.5%).
• 91% of participants on 10 mg achieved ≥5% weight loss vs. 35% on placebo (P<0.001).

These figures exceeded what had been reported for any approved obesity pharmacotherapy at the time of publication. NEJM, 2022

SURMOUNT-2: Patients With Type 2 Diabetes

SURMOUNT-2 (N=938) tested tirzepatide in adults with type 2 diabetes and obesity. Published in The Lancet in 2023, the trial showed weight loss of 13.4% with tirzepatide 10 mg and 15.7% with 15 mg at 72 weeks, compared to 3.3% for placebo. These reductions were substantially greater than those observed with GLP-1-only agents in similar populations.

SURMOUNT-MMO: Cardiovascular Events in Obesity

SURMOUNT-MMO is evaluating tirzepatide's effect on major adverse cardiovascular events in adults with obesity but without diabetes. Trial registration is documented at the NIH clinical trials registry. Full results are expected in 2025 and could expand the drug's use case to primary cardiovascular prevention.

Dosing Schedule and Titration

Tirzepatide follows a structured titration schedule designed to minimize gastrointestinal side effects during the dose-escalation phase.

Standard Titration Protocol

The FDA-approved titration schedule per the Mounjaro and Zepbound prescribing information:

| Week | Dose | |------|------| | 1 to 4 | 2.5 mg once weekly | | 5 to 8 | 5 mg once weekly | | 9 to 12 | 7.5 mg once weekly (if tolerated) | | 13 to 16 | 10 mg once weekly (if tolerated) | | 17 to 20 | 12.5 mg once weekly (if tolerated) | | 21 onwards | 15 mg once weekly (maintenance, if tolerated) |

The 2.5 mg starting dose is not a therapeutic dose for glucose or weight. Its sole purpose is tolerance induction. Clinicians may choose to hold a patient at any intermediate dose if side effects are limiting.

Injection Technique

Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Injection sites should be rotated each week. The FDA prescribing information for Mounjaro specifies that the pen must not be injected into muscle or a vein and should not be co-administered with insulin in the same site on the same day.

Side Effects and Safety Profile

Gastrointestinal Effects

Gastrointestinal adverse events are the most common reason for dose reduction or discontinuation. In SURMOUNT-1, nausea was reported by 31.0% of participants on 5 mg, 31.5% on 10 mg, and 28.9% on 15 mg, compared to 8.7% on placebo. Diarrhea affected 17 to 20% of tirzepatide participants across dose groups. NEJM, 2022 Most events were rated mild-to-moderate and occurred during dose escalation, resolving with time. Eating smaller, low-fat meals and avoiding high-fiber foods during titration reduces symptom severity.

Thyroid C-Cell Risk

All GLP-1 receptor agonists carry a black-box warning about the risk of thyroid C-cell tumors based on rodent studies. In rats, tirzepatide at all doses caused dose-dependent and treatment-duration-dependent C-cell adenomas and carcinomas. The FDA labeling explicitly states that the relevance to humans is unknown, but tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine calcitonin monitoring is not recommended but may be used at the clinician's discretion.

Pancreatitis and Gallbladder Disease

Acute pancreatitis has been reported with GLP-1-class agents. Tirzepatide should be discontinued if pancreatitis is confirmed. Rapid weight loss from any cause increases cholesterol secretion into bile, raising cholelithiasis risk. A 2022 meta-analysis in Alimentary Pharmacology and Therapeutics found GLP-1 receptor agonists as a class modestly increase gallbladder-related events, though absolute risk remains low.

Hypoglycemia

Tirzepatide does not cause clinically significant hypoglycemia when used as monotherapy. Because its insulin-stimulating effect is glucose-dependent (it falls away as blood glucose normalizes), the risk of going too low is inherently limited. The SURPASS-1 data published in Diabetes Care showed a 0% rate of documented symptomatic hypoglycemia <54 mg/dL in the tirzepatide arms when no sulfonylurea or insulin was co-administered. Patients on concomitant insulin or sulfonylurea do face increased hypoglycemia risk and may need dose reductions of those agents.

Heart Rate

A modest increase in resting heart rate of 1 to 4 beats per minute has been observed across tirzepatide trials, consistent with other GLP-1 class agents. The clinical significance of this finding in patients without pre-existing arrhythmia is considered low based on current data. See cardiovascular substudy data from SURPASS-2.

Comparing Tirzepatide to Semaglutide

Semaglutide (Ozempic, Wegovy) is the most widely used GLP-1 receptor agonist for diabetes and weight management. Tirzepatide adds GIP receptor activation on top of GLP-1 activity.

Head-to-Head Evidence

SURPASS-2 (discussed above) showed tirzepatide 15 mg outperformed semaglutide 1 mg on both A1C and weight. NEJM, 2021 No published head-to-head trial has yet compared tirzepatide to semaglutide 2.4 mg (Wegovy) for obesity specifically, though the SURPASS-SURMOUNT indirect comparison consistently favors tirzepatide for weight outcomes.

SURMOUNT-5: Direct Comparison Underway

SURMOUNT-5 is a head-to-head randomized controlled trial comparing tirzepatide 10 mg and 15 mg to semaglutide 2.4 mg for weight management in adults with obesity. The trial is registered and actively enrolling per the NIH. Results are anticipated in late 2025 and will provide the definitive weight-loss comparison.

Indirect Comparison Snapshot

• STEP-1 (N=1,961) with semaglutide 2.4 mg showed 14.9% mean weight loss at 68 weeks. NEJM, 2021
• SURMOUNT-1 with tirzepatide 15 mg showed 20.9% at 72 weeks. NEJM, 2022
• Trial populations differed slightly, so indirect comparisons carry uncertainty, but the magnitude gap is substantial.

Who Qualifies for Mounjaro or Zepbound?

Type 2 Diabetes (Mounjaro)

Mounjaro is indicated for adults with type 2 diabetes as an adjunct to diet and exercise. It carries no minimum BMI requirement for the diabetes indication. The American Diabetes Association's Standards of Care 2024 recommend GLP-1 receptor agonists with proven benefit as preferred agents in patients with established cardiovascular disease, heart failure, chronic kidney disease, or obesity, with tirzepatide now included as a preferred option given its trial profile.

Obesity and Overweight (Zepbound)

Zepbound (tirzepatide) is indicated for adults with:

• BMI ≥30 (obesity), or
• BMI ≥27 (overweight) plus at least one weight-related comorbidity.

Eligible comorbidities include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. Tirzepatide is not approved for cosmetic weight loss in individuals with BMI <27.

Who Should Not Use It

Absolute contraindications per FDA labeling:

• Personal or family history of medullary thyroid carcinoma.
• Multiple Endocrine Neoplasia syndrome type 2.
• Hypersensitivity to tirzepatide or any excipient.

Relative contraindications or precautions include a history of pancreatitis, severe gastrointestinal disease, pregnancy (weight-loss drugs should be stopped at least two months before planned conception per most clinical guidance), and diabetic retinopathy that could worsen with rapid glycemic improvement. ACOG guidance on obesity in pregnancy advises against continuing GLP-1 agents during pregnancy.

Insurance Coverage and Cost

List Price and Out-of-Pocket Costs

Mounjaro and Zepbound carry a list price of approximately $1,000 to $1,100 per month (four pens) in the United States as of early 2025, before insurance or manufacturer savings programs.

Eli Lilly Savings Card

Eli Lilly offers a savings card for commercially insured patients that can reduce out-of-pocket cost to $25 per month for Mounjaro in eligible patients with type 2 diabetes. Savings program details are described on the Eli Lilly patient assistance page. Zepbound savings are also available but vary by plan type.

Medicare and Medicaid Coverage

Medicare Part D currently covers Mounjaro for type 2 diabetes but has historically been prohibited from covering weight-loss drugs under the Treat and Reduce Obesity Act gap. Pending legislative changes may expand Zepbound coverage under Part D. Coverage under state Medicaid programs varies. CMS coverage guidance for anti-obesity medications continues to evolve.

What to Expect in the First Three Months

The first four weeks on 2.5 mg typically produce modest weight changes of one to two pounds as the body adjusts. Nausea may peak around weeks two to four during each dose escalation step. By week eight to twelve, most patients on 5 mg to 7.5 mg begin to notice meaningful appetite reduction and weight loss of five to ten pounds from baseline.

Clinical benchmarks from SURMOUNT-1 show patients who achieved ≥5% weight loss by week 20 were significantly more likely to achieve ≥20% loss by week 72. NEJM, 2022 If a patient has not lost at least 5% of body weight after 16 to 20 weeks at the maximum tolerated dose, the Endocrine Society's obesity pharmacotherapy guidance suggests reassessing the treatment plan. Endocrine Society Clinical Practice Guideline on Obesity

Long-Term Use and Weight Regain After Stopping

Maintenance Data

SURMOUNT-4 examined what happens when tirzepatide is discontinued after 36 weeks of active treatment. Participants who switched to placebo for an additional 52 weeks regained a mean of 14 percentage points of their lost weight, while those who continued tirzepatide maintained their losses and lost an additional 5.5%. Published in JAMA in 2024. This pattern mirrors data from semaglutide's STEP-4 trial and indicates that obesity, like hypertension or type 2 diabetes, requires ongoing pharmacotherapy for sustained benefit.

Implications for Clinical Planning

Patients considering tirzepatide should understand from the outset that stopping the medication is likely to result in partial weight regain. This does not mean the drug has failed. It means obesity has an underlying biology that requires continued management. The Obesity Medicine Association's position statement describes obesity as "a chronic, relapsing disease" requiring long-term treatment. Obesity Medicine Association position statement via PubMed.

Clinicians at HealthRX approach tirzepatide prescribing with a minimum 12-month commitment discussion so patients set realistic expectations before their first injection.